These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Spelman T; Frisell T; Piehl F; Hillert J Mult Scler; 2018 Jul; 24(8):1087-1095. PubMed ID: 28649912 [TBL] [Abstract][Full Text] [Related]
4. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. Lambe J; Risher H; Filippatou AG; Murphy OC; Sotirchos ES; Ehrhardt H; Ogbuokiri E; Pellegrini N; Toliver B; Luciano NJ; Davis S; Fioravante N; Kwakyi O; Prince JL; Calabresi PA; Fitzgerald KC; Saidha S Neurology; 2021 May; 96(20):e2525-e2533. PubMed ID: 33827962 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Khan O; Rieckmann P; Boyko A; Selmaj K; Ashtamker N; Davis MD; Kolodny S; Zivadinov R Mult Scler; 2017 May; 23(6):818-829. PubMed ID: 27503905 [TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years. Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831 [TBL] [Abstract][Full Text] [Related]
7. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis. Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858 [TBL] [Abstract][Full Text] [Related]
8. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Comi G; Filippi M; Wolinsky JS Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502 [TBL] [Abstract][Full Text] [Related]
10. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F; JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561 [TBL] [Abstract][Full Text] [Related]
12. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
13. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M; Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268 [TBL] [Abstract][Full Text] [Related]
14. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789 [TBL] [Abstract][Full Text] [Related]
15. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A Neurology; 2016 Jul; 87(2):141-7. PubMed ID: 27316241 [TBL] [Abstract][Full Text] [Related]
16. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Rovaris M; Comi G; Rocca MA; Wolinsky JS; Filippi M; Brain; 2001 Sep; 124(Pt 9):1803-12. PubMed ID: 11522582 [TBL] [Abstract][Full Text] [Related]
17. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580 [TBL] [Abstract][Full Text] [Related]